Learn More
Proteasome inhibition has been recognized as a novel treatment modality in hematologic malignancies. Initially, the reversible proteasome inhibitor bortezomib demonstrated efficacy in multiple myeloma (MM), which supported its approval for relapsed and refractory MM in 2003. Later on, carfilzomib, a next-generation irreversible proteasome inhibitor was(More)
which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. Summary Statement: In human dendritic cells, the membrane component of the NADPH oxidase NOX2 is initially recruited to phagosomes from the plasma membrane and oxidized NOX2 is replenished from a lysosomal pool. Abstract In(More)
BACKGROUND Radiotherapy is one of the mainstays in the treatment for cancer, but its success can be limited due to inherent or acquired resistance. Mechanisms underlying radioresistance in various cancers are poorly understood and available radiosensitizers have shown only modest clinical benefit. There is thus a need to identify new targets and drugs for(More)
Actin plays a critical role during the early stages of pathogenic microbe internalization by immune cells. In this study, we identified a key mechanism of actin filament tethering and stabilization to the surface of phagosomes in human dendritic cells. We found that the actin-binding protein SWAP70 is specifically recruited to nascent phagosomes by binding(More)
  • 1